At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 449 enrolled
Drug / intervention
voxelotor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease
In Brief
A Phase 3 clinical trial evaluating voxelotor and Placebo for Sickle Cell Disease. Completed, enrolled 449 participants across 62 sites in 12 countries.
Detailed Summary
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease
CountriesCanada, Egypt, France, Italy, Jamaica, Kenya, Lebanon, Netherlands, Oman, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedJan 2017
Primary CompletionOct 2019
TodayJul 2026
First PostedJan 30, 2017
Enrollment StartDec 1, 2016
Primary CompletionOct 8, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.4 years ago
Interventions
voxelotordrug
Placeboother